Re: Biogen Begins Phase III Study on Ischemic Stroke Candidate
Biogen has been given orphan drug status for this occasional reaction.
It's a virtual death sentence to be afflicted with severe cerebral edema because of a stroke, as if the more common effects aren't bad enough. It would be a real health boon if both Athersys's MultiStem and Biogen's drug for the occasional case of severe cerebral edema had significant efficacy. However, it's going to take Biogen a long trial-time to treat the number of patients required for statistical validity.